Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center

Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center

PURPOSEThe prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of utilization, tolerance, and outcomes with pomalidom...

Full description

Bibliographic Details
Main Authors: Suresh Kumar Bondili, Bhausaheb Bagal, Abhinav Zawar, Pradeep Ventrapati, Jayashree Thorat, Anant Gokarn, Sachin Punatar, Lingaraj Nayak, Avinash Bonda, Hashmukh Jain, Manju Sengar, Navin Khattry
Format: Article
Language:English
Published: American Society of Clinical Oncology 2021-12-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO.20.00228

Internet

https://ascopubs.org/doi/10.1200/GO.20.00228

Similar Items